Combination drug therapy for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (ivarmacitinib, camrelizumab, and fruquintinib) for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or recurrent colorectal cancer that has spread (metastatic).
- You must be between 18 and 75 years old.
- You must be physically active enough to do light or no activity (ECOG 0-1).
- You must have at least one tumor that can be measured on scans.
- You must have already tried at least two standard treatments for your cancer without success.
- You must not have had treatment with a JAK1 inhibitor before.
- You must be willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different drug combinations for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if one combination works as well as the other, potentially offering a new option.
This trial tests a new combination of drugs (cadonilimab, fruquintinib) plus targeted radiation (SBRT) for people with advanced MSS colorectal cancer who have already tried several standard treatments. The goal is to see if this combination can help shrink tumors or slow disease progression.
This trial tests a combination of two targeted drugs (Glumetinib and Fruquintinib) for people with a specific type of advanced colorectal cancer that has a change in the MET gene (amplification) or too much MET protein. It is for those whose cancer has not responded to at least two prior treatments.
This trial tests a new combination—an immunotherapy drug (cadonilimab) plus a targeted anti-angiogenesis pill (fruquintinib) and focused radiation (SBRT)—for people with MSS colorectal cancer that has progressed after at least two prior treatments. The goal is to see if this triple approach can help shrink or control the cancer better than standard options.
This trial tests a combination of two drugs and a liver-directed therapy for people with advanced colorectal cancer that has spread to the liver. It aims to see if this approach can help when standard first-line treatment has stopped working.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
Hear when a new Refractory Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.